Table 1. Characteristics of 15,872 NSCLC patients. Clinical characteristics of patients treated with the PD-(L)1 inhibitor in combination with bevacizumab, and PD-(L)1 inhibitor monotherapy.
| Characteristic | Combination therapy (n=409) | Anti-PD- (L)1 monotherapy (n=15,463) |
|---|---|---|
| Age, median (IQR), year | 65 [57–71] | 68 [61–74] |
| Weight, median (IQR), kg | 60 [53–72] | 64 [54–75] |
| Sex, No. (%) | ||
| Female | 250 (61.12) | 9,729 (62.92) |
| Male | 135 (33.01) | 4,669 (30.19) |
| Not reported | 24 (5.87) | 1,065 (6.89) |
| Country, No. (%) | ||
| Asia | ||
| Japan | 185 (45.23) | 5,560 (35.96) |
| China | 5 (1.22) | 319 (2.06) |
| Other | 16 (3.91) | 599 (3.87) |
| Non-Asia | ||
| United States of America | 38 (9.29) | 3,703 (23.95) |
| France | 22 (5.38) | 1,057 (6.84) |
| Other | 143 (34.97) | 4,225 (27.32) |
| Reporting year, No. (%) | ||
| 2013–2014 | 1 (0.24) | 56 (0.36) |
| 2015 | 5 (1.22) | 602 (3.89) |
| 2016 | 18 (4.40) | 2,009 (12.99) |
| 2017 | 52 (12.71) | 3,079 (19.91) |
| 2018 | 106 (25.92) | 4,765 (30.82) |
| 2019 | 227 (55.51) | 4,952 (32.03) |
IQR, interquartile range.